Status:
UNKNOWN
Effect of Milnacipran / Gabapentin in Fibromyalgia
Lead Sponsor:
Mansoura University
Conditions:
Fibromyalgia
Eligibility:
FEMALE
18-70 years
Phase:
NA
Brief Summary
Gabapentin and milnacipran (MLN) show strong evidence of reduced pain, increased sleep, and improvement in the quality of life in fibromyalgia (FM) patients. Most FM trials focus primarily on pain re...
Detailed Description
The aim of the study is to evaluate the analgesic efficacy of gabapentin-MLN as combined or monotherapy on patients with FM.
Eligibility Criteria
Inclusion
- There are no other criteria rather than age and sex
Exclusion
- Patient refusal.
- Pregnancy or breastfeeding.
- Active liver disease
- Renal impairment (creatinine clearance \< 60 mL/min).
- Documented autoimmune disease.
- Severe chronic obstructive pulmonary disease.
- Recent arrhythmia
- Myocardial infarction
- Stroke.
- Uncontrolled hypertension.
- Glaucoma.
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2023
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT05384210
Start Date
June 1 2022
End Date
November 1 2023
Last Update
May 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mansoura University
Al Mansurah, DK, Egypt, 050